Trial Profile
An open label, randomized, phase II study of AS1404 in combination with docetaxel in patients with hormone refractory metastatic prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Vadimezan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Aug 2008 Survival data reported by Antisoma in a media release.